Argilés JM, Busquets S, Stemmler B, López-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14:754–762. https://doi.org/10.1038/nrc3829

Article  CAS  PubMed  Google Scholar 

Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. https://doi.org/10.1016/S1470-2045(10)70218-7

Article  PubMed  Google Scholar 

von Haehling S, Anker SD (2014) Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014. J Cachexia Sarcopenia Muscle 5:261–263. https://doi.org/10.1007/s13539-014-0164-8

Article  Google Scholar 

Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Dueñas-González A (2017) Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. Am J Cancer Res 7:1107–1135

CAS  PubMed  PubMed Central  Google Scholar 

Arends J, Bachmann P, Baracos V et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11–48. https://doi.org/10.1016/j.clnu.2016.07.015

Article  PubMed  Google Scholar 

Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Futur Oncol 10:789–802. https://doi.org/10.2217/fon.14.14

Article  CAS  Google Scholar 

Graf SA, Garcia JM (2017) Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy. Drug Des Devel Ther 11:2325–2331. https://doi.org/10.2147/DDDT.S110131

Article  CAS  PubMed  PubMed Central  Google Scholar 

Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519–531. https://doi.org/10.1016/S1470-2045(15)00558-6

Article  CAS  PubMed  Google Scholar 

Katakami N, Uchino J, Yokoyama T et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non–small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606–616. https://doi.org/10.1002/cncr.31128

Article  CAS  PubMed  Google Scholar 

Hamauchi S, Furuse J, Takano T et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125:4294–4302. https://doi.org/10.1002/cncr.32406

Article  CAS  PubMed  Google Scholar 

Takayama K, Katakami N, Yokoyama T et al (2016) Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24:3495–3505. https://doi.org/10.1007/s00520-016-3144-z

Article  PubMed  PubMed Central  Google Scholar 

Shioda S, Takenoya F, Yagi M et al (2008) Neural networks of several novel neuropeptides involved in feeding regulation. Nutrition 24:848–853. https://doi.org/10.1016/j.nut.2008.06.016

Article  CAS  PubMed  Google Scholar 

Molfino A, Formiconi A, Rossi Fanelli F, Muscaritoli M (2014) Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care 17:471–476. https://doi.org/10.1097/MCO.0000000000000075

Article  CAS  PubMed  Google Scholar 

Amitani M, Asakawa A, Amitani H, Inui A (2013) Control of food intake and muscle wasting in cachexia. Int J Biochem Cell Biol 45:2179–2185. https://doi.org/10.1016/j.biocel.2013.07.016

Article  CAS  PubMed  Google Scholar 

Li QQ, Lu ZH, Yang L et al (2014) Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pacific J Cancer Prev 15:945–950. https://doi.org/10.7314/APJCP.2014.15.2.945

Article  Google Scholar 

Glen P, Jamieson NB, McMillan DC et al (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6:450–453. https://doi.org/10.1159/000094562

Article  PubMed  Google Scholar 

Read JA, Choy STB, Beale PJ, Clarke SJ (2006) Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 55:78–85. https://doi.org/10.1207/s15327914nc5501_10

Article  CAS  PubMed  Google Scholar 

Stokke K, Sandvei MS, Grønberg BH et al (2022) Prognostic value of post first-line chemotherapy Glasgow prognostic score in advanced non-small cell lung cancer. Clin Med Insights Oncol 16:0–7. https://doi.org/10.1177/11795549221086578

Article  Google Scholar 

Al Murri AM, Bartlett JMS, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230. https://doi.org/10.1038/sj.bjc.6602922

Article  CAS  PubMed  Google Scholar 

Paval DR, Patton R, McDonald J et al (2022) A systematic review examining the relationship between cytokines and cachexia in incurable cancer. J Cachexia Sarcopenia Muscle 13:824–838. https://doi.org/10.1002/jcsm.12912

Article  PubMed  PubMed Central  Google Scholar 

McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534–540. https://doi.org/10.1016/j.ctrv.2012.08.003

Article  PubMed  Google Scholar 

Krzystek-Korpacka M, Matusiewicz M, Diakowska D et al (2008) Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 46:359–364. https://doi.org/10.1515/CCLM.2008.089

Article  CAS  PubMed  Google Scholar 

Douglas E, McMillan DC (2014) Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow prognostic score. Cancer Treat Rev 40:685–691. https://doi.org/10.1016/j.ctrv.2013.11.007

Article  PubMed  Google Scholar 

Aoyagi T, Terracina KP, Raza A et al (2015) Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 7:17–29. https://doi.org/10.4251/wjgo.v7.i4.17

Article  PubMed  PubMed Central  Google Scholar 

Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030. https://doi.org/10.1038/sj.bjc.6601242

Article  CAS  PubMed  PubMed Central  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. (2017). Available online: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed 1 Sep 2022

van Buuren S (2007) Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 16:219–242. https://doi.org/10.1177/0962280206074463

Article  PubMed  Google Scholar 

Lee KJ, Tilling KM, Cornish RP et al (2021) Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework. J Clin Epidemiol 134:79–88. https://doi.org/10.1016/j.jclinepi.2021.01.008

Article  PubMed  PubMed Central  Google Scholar 

Iwai N, Sakai H, Oka K et al (2023) Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer 31:1–8. https://doi.org/10.1007/s00520-023-07576-y

Article  Google Scholar 

Arends J, Strasser F, Gonella S et al (2021) Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open 6:100092. https://doi.org/10.1016/j.esmoop.2021.100092

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roeland EJ, Bohlke K, Baracos VE et al (2020) Management of cancer cachexia: ASCO guideline. J Clin Oncol 38:2438–2453.